- Home
- ESLA vs SCYX Comparison
ESLA vs SCYX Comparison
Compare ESLA & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- SCYX
- Stock Information
- Founded
- ESLA 2021
- SCYX 1999
- Country
- ESLA United States
- SCYX United States
- Employees
- ESLA N/A
- SCYX N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- ESLA Health Care
- SCYX Health Care
- Exchange
- ESLA Nasdaq
- SCYX Nasdaq
- Market Cap
- ESLA 35.9M
- SCYX 34.9M
- IPO Year
- ESLA N/A
- SCYX 2014
- Fundamental
- Price
- ESLA $1.12
- SCYX $1.09
- Analyst Decision
- ESLA Strong Buy
- SCYX
- Analyst Count
- ESLA 1
- SCYX 0
- Target Price
- ESLA $16.00
- SCYX N/A
- AVG Volume (30 Days)
- ESLA 35.9K
- SCYX 237.7K
- Earning Date
- ESLA 08-12-2025
- SCYX 11-05-2025
- Dividend Yield
- ESLA N/A
- SCYX N/A
- EPS Growth
- ESLA N/A
- SCYX N/A
- EPS
- ESLA N/A
- SCYX N/A
- Revenue
- ESLA N/A
- SCYX $3,257,000.00
- Revenue This Year
- ESLA N/A
- SCYX $422.61
- Revenue Next Year
- ESLA N/A
- SCYX $240.56
- P/E Ratio
- ESLA N/A
- SCYX N/A
- Revenue Growth
- ESLA N/A
- SCYX N/A
- 52 Week Low
- ESLA $0.63
- SCYX $0.66
- 52 Week High
- ESLA $1.78
- SCYX $1.65
- Technical
- Relative Strength Index (RSI)
- ESLA 63.62
- SCYX 64.14
- Support Level
- ESLA $1.04
- SCYX $0.98
- Resistance Level
- ESLA $1.23
- SCYX $1.31
- Average True Range (ATR)
- ESLA 0.07
- SCYX 0.08
- MACD
- ESLA 0.01
- SCYX 0.01
- Stochastic Oscillator
- ESLA 56.00
- SCYX 56.00
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.